Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7419236 | 0.87 | GRM5 (1.00) | GRM5 | |
| SCHEMBL7420366 | 0.87 | GRM5 (1.00) | GRM5 | |
| SCHEMBL31061061 | 0.87 | GRM5 (1.00) | GRM5 | |
| SCHEMBL11966035 | 0.82 | GRM5 (0.77) | GRM5 | |
| SCHEMBL5794129 | 0.82 | GRM5 (0.70) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL187254 | 0.82 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL30273059 | 0.82 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL11966033 | 0.82 | GRM5 (0.81) | GRM5 | |
| Hydrochloric Acid SCHEMBL1803964 | 0.81 | GRM5 (0.97) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL7425347 | 0.81 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149721-A1 | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2010031114-A1 | NOVEL RECEPTOR HETERO-DIMERS/-OLIGOMERS | DIMERIX BIOSCIENCE PTY LTD (AU) | 2010-03-25 | — | — | WO | disclosed |
| US-20090239888-A1 | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-30 | — | — | US | disclosed |
| EP-2010174-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | The Regents of the University of California (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007124348-A2 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070060618-A1 | Alkyne derivatives as tracers for metabotropic glutamate receptor binding | MERCK & CO., INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2004038374-A2 | ALKYNE DERIVATIVES AS TRACERS FOR METABOTROPIC GLUTAMATE RECEPTOR BINDING | MERCK & CO., INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1214303-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016121-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM5 13/4885CYP1A2 4845/4885CYP2D6 4853/4885 |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM5 15/4885CYP1A2 4845/4885CYP2D6 4854/4885 |
| US-20070060618-A1 | Alkyne derivatives as tracers for metabotropic glutamate receptor binding | GRM5, GRM3, GRIK5 | GRM5 1/4885CYP1A2 2258/4885CYP2D6 1435/4885 |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM5 15/4885CYP1A2 4845/4885CYP2D6 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.